William Rote Sells 2,763 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider William Rote sold 2,763 shares of the business’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total value of $121,433.85. Following the completion of the transaction, the insider owned 115,474 shares in the company, valued at approximately $5,075,082.30. This trade represents a 2.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Trading Down 4.7%

NASDAQ:TVTX opened at $42.66 on Friday. The company has a debt-to-equity ratio of 3.16, a quick ratio of 2.70 and a current ratio of 3.13. Travere Therapeutics, Inc. has a one year low of $13.88 and a one year high of $48.61. The business’s 50-day simple moving average is $32.83 and its 200 day simple moving average is $32.94. The stock has a market cap of $3.97 billion, a price-to-earnings ratio of -185.47 and a beta of 1.13.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Monday, May 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The business had revenue of $127.20 million for the quarter, compared to analysts’ expectations of $136.23 million. During the same quarter in the previous year, the firm posted ($0.47) earnings per share. The company’s revenue was up 55.6% compared to the same quarter last year. As a group, sell-side analysts predict that Travere Therapeutics, Inc. will post -0.18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Travere Therapeutics

Institutional investors have recently made changes to their positions in the stock. State of Wyoming bought a new position in shares of Travere Therapeutics during the fourth quarter valued at approximately $37,000. Torren Management LLC bought a new position in Travere Therapeutics in the 4th quarter worth approximately $38,000. Comerica Bank grew its holdings in Travere Therapeutics by 77.5% in the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock worth $43,000 after buying an additional 492 shares in the last quarter. Fifth Third Bancorp bought a new position in Travere Therapeutics in the 1st quarter worth approximately $35,000. Finally, Smartleaf Asset Management LLC grew its holdings in Travere Therapeutics by 69.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock worth $45,000 after buying an additional 487 shares in the last quarter.

Analyst Ratings Changes

Several analysts have issued reports on TVTX shares. HC Wainwright upped their price objective on Travere Therapeutics from $47.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday. Piper Sandler upgraded Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 price objective on the stock in a research note on Tuesday, April 14th. Canaccord Genuity Group upped their price objective on Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a research note on Tuesday, April 14th. Citigroup upped their price objective on Travere Therapeutics from $53.00 to $59.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Guggenheim upped their price objective on Travere Therapeutics from $54.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $47.83.

Key Stories Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analyst upgrades and price?target increases — Wells Fargo moved to “overweight” and raised its target to $50, joining several firms that have lifted targets and reiterated buy ratings, which supports buying interest. Read More.
• Positive Sentiment: Q1 results showed an EPS beat and ~55.6% year?over?year revenue growth, giving fundamental support for the analyst optimism and helping justify a higher valuation multiple. Read More.
• Neutral Sentiment: Priced upsized convertible notes ($475M of 0.50% convertible senior notes due 2032) to refinance 2029 convertibles — this improves near?term liquidity and extends maturity but could be dilutive if converted; closing expected May 11. Read More.
• Neutral Sentiment: HC Wainwright trimmed some near? and mid?term EPS forecasts (Q2/FY2026–FY2030 tweaks) but kept a Buy rating and $57 target — modest estimate changes that haven’t removed analyst support. Read More.
• Neutral Sentiment: Management will present at multiple investor conferences in May–June (BofA, Jefferies, Goldman Sachs), offering upcoming opportunities for fresh guidance or investor Q&A. Read More.
• Negative Sentiment: Heavy insider selling disclosed (CEO, directors and several executives sold shares, often under pre?arranged Rule 10b5?1 plans and to cover tax obligations); the scale of sales — including the CEO’s 22,500?share sale — can create short?term supply and investor concern despite plan disclosures. Read More. Read More.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.